cyrilzakka/clinical-trials huggingface dataset:
Expressive Writing in GVHD

Graft-versus-host-disease (GVHD) is a disease phenomenon that occurs when immune cells of the donor recognize and attack healthy tissue within the transplant recipient, or host. It is ultimately the result of the same immunological mechanisms that provide benefit to patients receiving hematopoietic stem cell transplantation (HSCT). In patients with hematologic malignancies, HSCT can be therapeutic, as donor T cells recognize and mount a response against cancerous cells. HSCT is also used in the setting of certain immunodeficiencies and inborn errors of metabolism for which therapeutic benefit is found in immunologic repletion.

To our knowledge, support groups have yet to be investigated in academic literature as a nonpharmacologic, therapeutic intervention for cutaneous GVHD patients to improve their distress, systemic disease, and quality of life. Given the dearth of research on nonpharmacologic therapies for cutaneous GVHD that address quality of life impairments, we seek to characterize the effect of an expressive writing and peer helping intervention contextualized within the framework of a support group. The primary goal of this study is to provide preliminary efficacy data of expressive writing as an intervention in patients with cutaneous GVHD to trial.


Eligibility Criteria:
Inclusion Criteria:

* Patients must have an active or previously diagnosed chronic cutaneous graft-versus-host disease (cGVHD).
* Patients must be age ≥18 years.
* Patients must be able to write using a utensil and paper or be able to type.
* Patients must have access to internet or cellular connectivity with sufficient bandwidth to participate in videoconferences (Zoom).
* Patients should be able to and planning to attend all four live videoconferencing sessions for the support group via Zoom.
* Patients must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Patients with limited level of oral and written English.
PIR of Quadratus Lumborum With and Without Gluteus Maximus Activation in Innominate Upslip Suprapubic Dysfunction

The innominate up slip dysfunction is the most common in athletes and non-athletes, who present with low back pain and sacroiliac dysfunction. The main muscular structure that forms the force closure of the joint involves the bicep femoris and gluteus maximus that are involved in the stability of the of the pelvis through immense attachments through the Sacro-tuberous ligament. The objective of this study is to determine the effectiveness of Post Isometric Relaxation (PIR) of Quadratus lumborum with and without Gluteus maximus activation on pain, disability and pelvic tilt angle in patients with innominate upslip suprapubic dysfunction.

The study will be a randomized controlled trial involving 34 patients both males and females aged 20 to 40 years with history of unilateral pelvic pain not radiating to L5 or above, Positive finding of sitting flexion test, standing flexion tests, stork test and Positive active straight leg raise test will be randomly recruited by consecutive sampling technique. The subjects having ankylosing spondylitis, lumbar radiculopathy, spinal pathologies, or any lumbar fracture will be excluded. All the patients in the study will be randomly assigned into two groups where Group A will be given muscle energy technique of quadratus lumborum along with gluteus maximus activation and Group B will be a control group treated with muscle energy technique only. Both groups will be given buttock squeezing and drawing in maneuver as common treatment along with muscle energy technique. Each session will be repeated for 20 minutes thrice a week. The treatment duration will be 4 weeks. Outcomes will be measured at the first day and then at the end of the 4th week by numeric pain rating scale, modified Oswestry disability index and iHandy inclinometer application. .


Eligibility Criteria:
Inclusion Criteria:

1. Patients aged 20 to 40 years
2. Both males \& females
3. History of unilateral pelvic pain not radiating to L5 or above
4. Positive finding of sitting flexion test, standing flexion tests, stork test.
5. Positive active straight leg raise test

Exclusion Criteria:

1. Subjects diagnosed with ankylosing spondylitis.
2. Lumbar radiculopathy
3. Spinal pathologies including spondylosis and spondylolisthesis.
4. Subjects immediately post pregnancy.
5. Disc herniation
6. Lumbar fractures or spinal surgeries
Anti-adhesive Effect and Safety of "Thermo-sensitive Adhesion Barrier (MEDICLORE)"

One of most important complication of thyroid surgery is adhesion. There are many anti-adhesive materials, but none of them showed significant outcomes. The investigators planned double blind prospective study of "Thermo-sensitive Adhesion Barrier (MEDICLORE)" to reveal anti-adhesive effect of MEDICLORE. The investigators will recruit total 90 patients (control group 45, experimental group 45) and compare postoperative outcomes about adhesion.


Eligibility Criteria:
Inclusion Criteria:

* planned to perform thyroidectomy due to thyroid nodule
* no evidence of distant metastasis or invasion to adjacent organ in thyroid cancer
* normal preoperative vocal cord movement
* normal preoperative laboratory study

Exclusion Criteria:

* uncontrolled hypertension, diabetes, chronic renal failure, coagulopathy
* history of keloid or hypertrophic scar
* Graves disease or hashimoto thyroiditis patients
* aspirin or anticoagulant medication within 7 days
* radiation exposure to the head and neck
* previous operation to the neck
* history of allergic reaction to drugs
* pregnant women
Role of Home-based Transcutaneous Electrical Acustimulation for Treatment of Pain in Patients With Chronic Pancreatitis

This research is studying a new noninvasive device-based therapy called Transcutaneous Electrical Acustimulation (TEA) to learn about its safety and how well it works as a treatment of pain in chronic pancreatitis. The purpose of this study is to investigate the potential of TEA to treat abdominal pain in patients with chronic pancreatitis (CP).

The study hypothesizes that TEA can be used as a non-pharmaceutical opioid-free approach to treat pain in chronic pancreatitis.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of chronic pancreatitis (CP), based on a score greater or equal to 4 using a previously validated Mayo scoring system that uses morphologic and functional criteria, or endosonographic features suggestive or consistent with CP based on Rosemont criteria.
* Abdominal pain present at least once within the last month
* Willing and able to provide written informed consent

Exclusion Criteria:

* Pregnancy or breastfeeding mother
* Imprisoned individuals
* Non-English speaking patients
* Scheduled for or with a history of pancreatic surgery (e.g. Total Pancreatectomy with Islet Auto Transplantation (TPIAT), Puestow, Frey, Whipple, other)
* Currently undergoing or about to start endoscopic therapy with Endoscopic retrograde cholangiopancreatography (ERCP) or Endoscopic ultrasound (EUS)
* Recent history of acute pancreatitis as defined by the Revised Atlanta Classification within a month prior to enrollment
* Radiologic and clinical findings consistent with symptomatic pseudocyst, wall-off necrosis, infected pancreatic necrosis, or biliary obstruction within the last 6 months
* Self-reported daily use of opioids for \> 12 months for weak opioids (codeine, tramadol and hydrocodone) or \> 6 months for strong opioids (other opioids) in the last two years.

-Self-reported ongoing illicit drug use or abuse-

* Suspected or diagnosed pancreatic cancer
* Receiving chemotherapy for cancer
* Known allergy to adhesive electrocardiogram (ECG) electrodes
* Patients with bilateral below the knee amputation
* Patients with lower extremity paralysis
* Patient is participating in another clinical trial
* Patients with an implantable electrical stimulation device.
The Spinopelvic Parameters, Body Mass Index and Waist Circumference in Patientd Chronic Non-specific Low Back Pain

This pilot study aims at styding the correlations between body mass index, waist circumference and the potential for positional adaptation of the pelvis to support overweight or obesity

Record cards of patients presenting with non specific low back pain between January 1st 2020 and December 23rd 2022 were analysed.

All included patients had undergone a full spine X-ray allowing to calculate the pelvic index (PI). Weight status was described in 4 categories, in-line with the WHO definitions; Underweight (boddy mass index (BMI)) \< 18.5 kg/m²; normal weight BMI 18.5 - 24.9 kg/m² , overweight BMI 25 - 29.9 kg/m², and obesity BMI ≥ 30 kg/m². To identify people with increased BMI-values and central (abdominal) fat distribution, we used the waist circumference (WC). The cut-off points of waist measurement that are used are 102 cm and 88 cm for men and women respectively. A high sacral slope (SS) means a greater the lumbar curvature, which results in a dynamic back. Due to the correlation between SS and PI, people with high PI values generally have higher values of SS. Therefore types 1 and 2 have a low-grade PI and types 3 and 4 have a high-grade PI Analysis of 272 patient records, shows that the mean PI is significantly different in the group with a low WC compared with the group with a high WC. BMI and WC show a significant correlation with PI

Eligibility Criteria:
Inclusion Criteria:

* presenting with non-specific low back pain
* having undergone full spine X-ray during the diagnostic proces

Exclusion Criteria:

* patients with missing data
* double entry of patients
A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis

Identifying the role of antibiotics in the treatment of subjects with a microbiologically documented acute exacerbation of chronic bronchitis (AECB) is the purpose of this clinical trial. The trial has been designed to evaluate the efficacy and safety of faropenem medoxomil versus placebo in the treatment of subjects with microbiologically documented AECB.

This is a multi-center, multi-national, prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety/tolerability of faropenem medoxomil versus placebo in the treatment of subjects with a primary diagnosis of AECB. All subjects will have a pre-therapy sputum specimen obtained for culture and susceptibility testing.

Eligibility Criteria:
Inclusion Criteria:

* Male or non-pregnant female outpatients age greater than or equal 35 years with significant COPD (GOLD criteria I, IIA or IIB), chronic cough and sputum production and an acute exacerbation

Exclusion Criteria:

* Gold criteria III
Using Bite Counter for Weight Loss: A One-month Usability Trial to Test the Effectiveness of Using the Bite Counter

This is a 1-month study that will examine the use of podcasting and a wearable wrist-worn device to track calorie intake and promote weight loss. A podcast is a digital audio file that can be listened to on portable media players, like iPods, and personal computers. This study will run from July 14, 2015 to August 11, 2015. In this study, you will receive weight loss information delivered via twice weekly podcasts. You will also track each meal you eat by wearing a provided watch-like device.

This study will last approximately 1 month (about 4 weeks). Participants will need to attend one 1.5-hour orientation meeting, baseline assessment, and training meeting, and then weekly 1-hour meetings for four weeks (5 meetings total). Participants will listen to 2 podcasts per week and will be encouraged to monitor exercise and body weight and track each meal using the provided wearable, wrist worn device. Each of the podcasts will take about 15 - 20 minutes to listen to and so participants should expect to spend 30 - 40 minutes each week listening to podcasts and up to 3 hours completing other study-related activities each week-including attending the weekly meetings-for a total of about 4 hours per week.

Eligibility Criteria:
Inclusion Criteria:

* 18-65 years of age
* BMI between 25- 49.9 kg/m2
* live in Columbia, South Carolina area
* be able to attend all assessment visits
* have access to the Internet, a computer, and a smartphone (iPhone, Android, etc.)
* have MD consent for participation if currently on blood pressure medications, have issues with dizziness, or have bone or joint issues
* be free of an eating disorder as screened by the Eating disorder Screen for Primary care. (If a participant has an eating disorder, they will be referred to their family physician)
* no current participation in a weight loss program or taking weight loss medications (although participants may be trying to lose weight on their own)
* able to prepare all their own meals (i.e. not living on-campus)

Exclusion Criteria:

* major health or psychiatric diseases, drug or alcohol dependency, thyroid conditions, or pregnancy
* pregnant (or have been pregnant in the last 6 months), anticipating on becoming pregnant in the next 7 months, or currently breastfeeding o Women who are pregnant should not be pursuing weight loss and should be under the direct care of a physician. Therefore women who are pregnant or who are anticipating they might be pregnant should not participate in this study. If a woman becomes pregnant during the study, she will be advised to consult her care provider and will be dropped from the weight loss study.
CPR Decision Aid For Patients With Advanced Gynecologic Malignancies

The purpose of this research is to assess the effect of a cardiopulmonary resuscitation (CPR) decision aid video on CPR knowledge and end-of-life preferences in women with advanced gynecologic malignancy. We will assess the baseline CPR knowledge in our research population, gauge the improvement after viewing a decision aid video, and evaluate its effects on patient preferences regarding CPR.


Eligibility Criteria:
Inclusion Criteria:

* patients with stage III or greater cervical, ovarian, or uterine malignancies
* receiving chemotherapy at UAB gynecologic oncology infusion center

Exclusion Criteria:

* early stage gynecologic cancer
* receiving chemotherapy at a different location
* Non-English speaking
* deafness
* blindness
Surveillance Study of the Contraceptive Intrauterine Device UT380®

The study is a long term Post Market Surveillance Study involving women who will received UT 380® device as a contraceptive method.

Prospective data on contraceptive performance of the UT380® from a large number of women are not yet available. Here we describe a long term Post Market Surveillance Study involving women who will received UT 380® device as a contraceptive method. Reports of case series usually contain detailed information about the individual patients. This includes demographic information (e.g. age and gender) and information on diagnosis, treatment, response to treatment, follow-up after treatment and patients experience of the treatment. In addition, it also include the health care staff's experience of the use of the UT 380. The result of this study will be used for different purposes e.g. marketing activities such as posters, folders, or targeted journals and/or conferences.

Eligibility Criteria:
Inclusion Criteria:

* Woman \> 18 years old
* nulliparous, uniparous and multiparous
* not currently using a contraceptive method or are willing to switch to a new reversible contraceptive
* with an indication of implantation of a UT380® IUD
* agreeing to participate in the study

Exclusion Criteria:

* Patient with risk of post implantation bleeding or high level of bleeding during menstruation period
* Patient with a risk of infection
* Patient that meet any of the absolute contraindication of UT 380®
* Any other elements that the investigator may think relevant and cannot allow the use of UT380®
Evaluation of New Specifications (38mm) of FirehawkTM in the Treatment of Coronary Heart Disease

The purpose of this study is to evalute the clinical safety and effectiveness of released specification (38mm) of FirehawkTM Sirolimus target-eluting coronary stent system.


Eligibility Criteria:
Inclusion Criteria:

1. 18-80 years of age, males or non-pregnant women;
2. Evidence of silent ischemia, stability or in patients with old myocardial infarction or unstable angina;
3. Primary target lesion, in situ coronary artery disease;
4. Target lesion length ≤ 60mm, target lesion diameter 2.75mm or 4.0mm (Visual method);
5. The target lesion diameter stenosis ≥ 70% (Visual method);
6. Each target lesion implantation the same stent (Firehawk stand);
7. With indications for coronary artery bypass surgery;
8. To understand the purpose of testing, voluntary and informed consent, patients undergoing invasive imaging follow-up.

Exclusion Criteria:

1. Within 72h of any acute myocardial infarction;
2. Unprotected left main coronary artery disease, triple vessel lesions which need treated all;
3. Severe calcified lesions that cannot be successfully expanded and distorting lesions not suitable for stent delivery;
4. Artery and/or vein bypass graft lesions;
5. Intracoronary implantation of any branding stents within 1 year;
6. Severe congestive heart failure (NYHA class III and above), or left ventricular ejection fraction \<35% (ultrasound or left ventricular angiography);
7. Preoperative renal function serum creatinine \>2.0mg/DL;
8. Bleeding, active gastrointestinal ulcers, brain hemorrhage or subarachnoid hemorrhage and half year history of ischemic stroke, antiplatelet agents and would not allow an anticoagulant therapy contraindications patients undergoing antithrombotic therapy;
9. Aspirin, clopidogrel, heparin, contrast agent, poly lactic acid polymer and rapamycin allergies;
10. The patient's life expectancy is less than 12 months;
11. Top participated in other drug or medical device and does not meet the primary study endpoint in clinical trials time frame;
12. Researchers determine patient compliance is poor, unable to complete the study in accordance with the requirements;
13. Heart transplantation patients.
Comparing Post-Surgical Symptoms: Gastric Sleeve With and Without Omentopexy "Comparing Post-Surgical Symptoms: Gastric Sleeve With and Without Omentopexy" Comparison of Postoperative Symptoms: Gastric Sleeve With and Without Omentopexy.

Metabolic surgery has proven to be an effective treatment for obesity, with laparoscopic sleeve gastrectomy being the most popular procedure. Omentopexy (OP) is proposed as a strategy to reduce associated complications. Objective was to determine the effectiveness of omentopexy in controlling post-surgical symptoms and to measure the need for re-intervention, leakage, bleeding, and mortality in patients undergoing laparoscopic sleeve gastrectomy.

Patients who underwent laparoscopic sleeve gastrectomy (LSG). Of these patients, 53 received LSG with omentopexy (OP) and 52 underwent LSG without omentopexy (NO OP) between 2022 and 2023. Each group was attended by a different surgeon. The analysis focused on data concerning gastrointestinal symptoms recorded 24 hours postoperatively, as well as documented cases of bleeding, leakage, re-operation, and mortality during the hospitalization period

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of obesity
* Adults over 18 years old
* Undergoing sleeve gastrectomy
* Consent to respond to the immediate postoperative symptom questionnaire

Exclusion Criteria:

* Repair of hiatal hernia
* Refusal to complete the evaluation instrument
* Unavailability of medical records
Study of the Pathogenesis and Molecular Mechanism of "YURE" in Internal Intractable Diseases

The purpose of this study is to determine whether the Chinese herbs formula is effective in the treatment of hemorrhagic stroke and to find out Chinese pathogeny and pathogenesis in the disease.

Blood stasis and blood heat are two pathogens in the theory system of Chinese Medicine, which can cause many diseases independently. But in internal intractable diseases, such as viral hepatitis, stroke, and epidemic hemorrhagic fever, blood stasis and blood heat always accompany with each other. So the hypothesis is raised that blood stasis with heat (YURE) is a compound pathogen and key pathogenesis in internal intractable diseases. This study was aimed to verify the role that the compound pathogen played in hemorrhagic stroke and to observe the progress of the key pathogenesis. A randomized and controlled trial would be conducted in five hospitals, where 300 hospitalized patients with hemorrhagic stroke in the acute phase would receive different intervention with basic modern medicine treatment or Chinese herbs formula combined with the former. The Chinese herbs formula, which was designed under the guidance of the theory system of Chinese Medicine, was supposed to cool blood heat and dissolve blood stasis. Clinical efficacy and safety would be evaluated after the 21-days intervention.

Eligibility Criteria:
Inclusion Criteria:

* clinical diagnosis of hemorrhagic stroke
* hospitalized in 48 hours after hemorrhagic stroke happens

Exclusion Criteria:

* Subarachnoid Hemorrhage
* intracranial hemorrhage caused by tumor, trauma or blood diseases
Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer

The main objectives of this trial are:

1. To assess the activity and safety of pantoprazole and docetaxel (with prednisone) in men with metastatic CRPC who have not received prior chemotherapy.
2. To evaluate archival prostate cancer tissue of men included in the clinical trial for evidence of autophagy using IHC for LC3B, ATG5, p62 as well as ERG.
3. To evaluate pharmacokinetic interactions of pantoprazole with docetaxel.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥18yrs
* ECOG performance status ≤2
* Histologically or cytologically confirmed adenocarcinoma of the prostate
* Clinical or radiological evidence of metastatic disease
* Disease progression while receiving androgen deprivation therapy with an increase in PSA of 25% or greater over nadir value measured on 3 consecutive occasions at least 1 week apart
* Antiandrogen therapy must have been stopped at least 4 weeks prior to start of trial treatment (6 weeks in the case of bicalutamide or nilutamide)if there was a reduction in serum PSA after this therapy was initiated
* Baseline serum prostate-specific antigen (PSA)≥10ng/ml
* Total testosterone \<50 ng/dL (\<1.7 nmol/L)
* Adequate hematologic values: neutrophil count ≥1,500/mm3, platelet ≥100,000/mm3, hemoglobin ≥10.0 g/dl
* Adequate hepatic and renal function: total bilirubin level ≤1.5 x ULN (unless secondary to documented Gilbert's disease); ALT,AST, and creatinine ≤1.5 x ULN
* Ability to understand and to sign consent for the study

Exclusion Criteria:

* Prior treatment for prostate cancer with chemotherapy or radioisotopes
* History of another cancer within the preceding five years (except basal or squamous-cell skin cancer or adequately treated superficial bladder cancer)
* Known or suspected brain or leptomeningeal metastases
* Symptomatic peripheral neuropathy of grade 2 or higher
* Major surgery within 4 weeks of start of trial treatment
* Radiotherapy to ≥25% of the bone marrow and any radiotherapy within 4 weeks of start of trial treatment
* Known hypersensitivity to trial treatment or hypersensitivity to any of its components
* Any concomitant drugs contraindicated for use with the trial treatment
* Any serious underlying medical condition which could impair the ability of the patient to participate in the trial
* Any psychological, familial, sociological or other patient related factors that might preclude compliance with the study protocol